Tovorafenib approved by the FDA: breakthrough treatment for low-grade glioma in children with BRAF mutation 26/09/2025
A new generation of Menin inhibitors revolutionizes the treatment of acute leukemia, giving Hong Kong patients new hope 23/09/2025
Retifanlimab-dlwr is used to treat metastatic or recurrent locally advanced Merkel cell carcinoma 21/09/2025
Zenocutuzumab: FDA approves new bispecific antibody for the treatment of NRG1 gene fusion cancer 19/09/2025
The U.S. Food and Drug Administration (FDA) approved the IDH1/2 inhibitor Vorasidenib for patients with specific astrocytoma or oligodendrocytoma 17/09/2025
Immunotherapy combined with chemotherapy for the treatment of advanced gastric cancer/gastroesophageal junction adenocarcinoma: Analysis of the results of DURIGAST PHASE II trial 15/09/2025
FDA accelerated approval of Tovorafenib for the treatment of low-grade glioma patients with recurrent or refractory BRAF gene variants in children 13/09/2025
